REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody tested for Tough-to-Treat blood cancers
Disease control CompletedThis early-stage trial tested a new antibody drug called flotetuzumab in 13 patients with advanced blood cancers that had returned or stopped responding to standard treatments. The main goal was to find the safest dose and understand the drug's side effects. Researchers also look…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for toughest lymphomas: experimental combo targets Cancer's repair system
Disease control CompletedThis early-stage study tested a new combination of drugs for patients with aggressive lymphomas that have come back or not responded to standard treatments. The main goal was to find the safest dose of a drug called olaparib when given with a powerful chemotherapy regimen before …
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for tough-to-treat hodgkin lymphoma patients
Disease control CompletedThis study tested a combination of a targeted cancer drug (brentuximab vedotin) with three chemotherapy drugs for patients whose Hodgkin lymphoma returned or didn't respond to previous treatment. The trial aimed to find the safest dose and see how well this combination worked to …
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC